General Information of Drug (ID: DR3207)
Drug Name
RDEA3170
Synonyms .
Indication Hyperuricaemia [ICD11: 5C55] Phase 2 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 348.4 Topological Polar Surface Area 99.3
Heavy Atom Count 25 Rotatable Bond Count 4
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 5
Cross-matching ID
PubChem CID
54767229
CAS Number
1352792-74-5
TTD Drug ID
D0P3ZN
Formula
C20H16N2O2S
Canonical SMILES
CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N
InChI
InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)
InChIKey
YYBOLPLTQDKXPM-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
RDEA3170 Metabolite M1 DM018960 N. A. Conjugation - Glucuronidation 1 [2]
RDEA3170 Metabolite M4 DM018962 N. A. Oxidation - N-oxidation 1 [2]
RDEA3170 Metabolite M8 DM018961 N. A. Unclear - Unclear 2 [2]
RDEA3170 Metabolite M8 DM018961 N. A. Conjugation - Glucuronidation of N-oxide 2 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR011350 RDEA3170 RDEA3170 Metabolite M1 Conjugation - Glucuronidation Unclear [2]
MR011352 RDEA3170 RDEA3170 Metabolite M4 Oxidation - N-oxidation Unclear [2]
MR011351 RDEA3170 Metabolite M1 RDEA3170 Metabolite M8 Conjugation - Glucuronidation of N-oxide Unclear [2]
MR011353 RDEA3170 Metabolite M4 RDEA3170 Metabolite M8 Unclear - Unclear Unclear [2]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[2]
References
1 ClinicalTrials.gov (NCT02078219) Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia. U.S. National Institutes of Health.
2 Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.